TY - JOUR
T1 - Combination and Novel Pharmacologic Agents for OAB
AU - Clearwater, Whitney
AU - Kassam, Farzaan
AU - Aalami Harandi, Arshia
AU - Tenggardjaja, Christopher F.
AU - Abraham, Nitya
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/7
Y1 - 2022/7
N2 - Purpose of Review: To evaluate recent literature on combination and novel pharmacologic therapies for overactive bladder (OAB). Recent Findings: Combination therapies demonstrating greater efficacy than monotherapy include combination anticholinergics, anticholinergic plus β-3 agonist, and anticholinergic with behavioral modification, percutaneous tibial nerve stimulation, or sacral neuromodulation. Promising novel therapies include new bladder selective anticholinergics, new β-3 agonists, and gabapentin. Summary: OAB is a symptom complex caused by dysfunction in the interconnected neural, muscular, and urothelial systems that control micturition. Although several therapeutic targets and treatment options exist, complete resolution is not always achieved, discontinuation rate for medical therapy is high, and few patients subsequently progress to third-line treatment options. Recent literature suggests combination therapy diversifying therapeutic targets is more effective than targeting a single pathway and novel treatments targeting additional pathways have promising results.
AB - Purpose of Review: To evaluate recent literature on combination and novel pharmacologic therapies for overactive bladder (OAB). Recent Findings: Combination therapies demonstrating greater efficacy than monotherapy include combination anticholinergics, anticholinergic plus β-3 agonist, and anticholinergic with behavioral modification, percutaneous tibial nerve stimulation, or sacral neuromodulation. Promising novel therapies include new bladder selective anticholinergics, new β-3 agonists, and gabapentin. Summary: OAB is a symptom complex caused by dysfunction in the interconnected neural, muscular, and urothelial systems that control micturition. Although several therapeutic targets and treatment options exist, complete resolution is not always achieved, discontinuation rate for medical therapy is high, and few patients subsequently progress to third-line treatment options. Recent literature suggests combination therapy diversifying therapeutic targets is more effective than targeting a single pathway and novel treatments targeting additional pathways have promising results.
KW - Combination therapy
KW - Novel therapy
KW - Overactive bladder
UR - http://www.scopus.com/inward/record.url?scp=85130136001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130136001&partnerID=8YFLogxK
U2 - 10.1007/s11934-022-01097-7
DO - 10.1007/s11934-022-01097-7
M3 - Review article
C2 - 35567657
AN - SCOPUS:85130136001
SN - 1527-2737
VL - 23
SP - 129
EP - 141
JO - Current urology reports
JF - Current urology reports
IS - 7
ER -